Windlas Biotech Limited
WINDLAS
Rank in Stocks
#16370
Windlas Biotech Limited functions as a comprehensive contract development and... Windlas Biotech Limited functions as a comprehensive contract development and manufacturing organization (CDMO). Its CDMO offerings span the full product lifecycle, encompassing initial discovery, subsequent development, licensing, and large-scale commercial production of various generic pharmaceutical and nutraceutical items. Through these services, it assists clients in bringing both established and innovative pharmaceutical and nutraceutical products to market, which are then sold under the clients' proprietary brand names. Beyond its CDMO segment, Windlas Biotech also develops and manufactures its own portfolio of domestic trade generics and over-the-counter (OTC) brands, catering to the nutritional, ayurvedic, wellness, and personal care sectors. These in-house products reach consumers via a dual distribution approach: traditional offline channels like distributors, stockists, retail pharmacies, and institutional tenders, alongside a robust online presence through various e-commerce platforms. The company's international reach extends through exports, primarily to markets such as Vietnam, Myanmar, Sri Lanka, Thailand, the Philippines, Cambodia, Fiji, Trinidad & Tobago, and South Africa. Established in 2001, Windlas Biotech is headquartered in Gurugram, India.
Share Price
$10.37
Last synced: 2026-11-09
Market Cap
$214.00M
Change (1 day)
-1.49%
Change (1 year)
9.50%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Windlas Biotech Limited (WINDLAS)
Category
Healthcare
Operating Margin for Windlas Biotech Limited (WINDLAS)
Operating Margin as of November 2026 TTM: 7.90%
According to Windlas Biotech Limited's latest financial reports, its current operating margin (TTM) is 7.90%. At the end of 2025 the company had an operating margin of 8.70%.
Operating Margin history for Windlas Biotech Limited from 2018 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 7.90% | -9.20% |
| 2025 | 8.70% | -16.10% |
| 2024 | 10.37% | 10.44% |
| 2023 | 9.39% | 8.06% |
| 2022 | 8.69% | -14.55% |
| 2021 | 10.17% | 2.73% |
| 2020 | 9.90% | -0.30% |
| 2019 | 9.93% | 55.64% |
| 2018 | 6.38% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 19.41% | -97.54% |
DE
|
|
| 19.68% | -97.51% |
DE
|
|
| 13.26% | -98.32% |
JP
|
|
| 17.08% | -97.84% |
CH
|
|
| 14.92% | -98.11% |
IL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Windlas Biotech Limited's operating margin
What is Windlas Biotech Limited's operating margin?
Windlas Biotech Limited's operating margin is 7.90%, as of Nov 2026.
What was Windlas Biotech Limited's operating margin in 2025?
In 2025, Windlas Biotech Limited's operating margin was 8.70%, compared with 10.37% in 2024.
How has Windlas Biotech Limited's operating margin changed since 2020?
From 2020 to 2025, Windlas Biotech Limited's operating margin was highest in 2024 (10.37%) and lowest in 2022 (8.69%).
How does Windlas Biotech Limited's operating margin compare with similar companies?
Windlas Biotech Limited's operating margin (7.90%) is lower than that of all 5 similar companies listed above. The highest among them is Merck KGaA, with 19.68%.